EARNEST Partners’s Meridian Bioscience Inc VIVO Stock Holding History

EARNEST Partners’s Portfolio VIVO Stock Details VIVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-141	Closed	-$4.68K	–	1182
2022 Q4	$4.68K	Hold	141	–	–	﹤0.01%	804
2022 Q3	$4K	Sell	141 -3,564,922	-100%	-$115M	﹤0.01%	859
2022 Q2	$108M	Sell	3,565,063 -91,880	-3%	-$2.48M	0.72%	53
2022 Q1	$94.9M	Sell	3,656,943 -67,367	-2%	-$1.6M	0.56%	72
2021 Q4	$76M	Sell	3,724,310 -179,250	-5%	-$3.44M	0.44%	89
2021 Q3	$75.1M	Buy	3,903,560 +17,812	+0.5%	+$355K	0.46%	88
2021 Q2	$86.2M	Sell	3,885,748 -456,086	-11%	-$9.67M	0.51%	79
2021 Q1	$114M	Buy	+4,341,834	New	+$103M	0.68%	58

Other funds holding VIVO

BTI

Blue Trust Inc Alpharetta, Georgia $8.74B AUM 14.62% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

EARNEST Partners's VIVO Position: Q1 2023 in Review

EARNEST Partners sold out of Meridian Bioscience Inc (VIVO) in Q1 2023, closing a stake of 141 shares — an estimated $4.68K sold.

EARNEST Partners first reported a position in VIVO in Q1 2021 and held it in 8 quarters. The position peaked at $114M in Q1 2021. 2 funds tracked by Wall St. Rank hold VIVO as of Q1 2023.

EARNEST Partners reported no remaining Meridian Bioscience Inc position as of Q1 2023 after selling out during the quarter.
EARNEST Partners sold 141 Meridian Bioscience Inc shares in Q1 2023, an estimated $4.68K.
EARNEST Partners first reported a position in Meridian Bioscience Inc in Q1 2021 and held it in 8 quarters.
EARNEST Partners's Meridian Bioscience Inc position peaked at $114M in Q1 2021.
2 funds tracked by Wall St. Rank held Meridian Bioscience Inc as of Q1 2023.

Based on EARNEST Partners's 13F filing for Q1 2023, filed 15 May 2023.